HOD Viva Questions — 37F, Nulligravida, 12×10 cm Posterior Intramural Fibroid with Cystic Degeneration, Fertility Preservation Desired

🔷 SECTION 1: CASE COMPREHENSION & DIAGNOSIS

• Type 0: Pedunculated intracavitary
• Type 1: <50% intramural (submucosal)
• Type 2: ≥50% intramural (submucosal)
• Type 3: Contacts endometrium, 100% intramural
• Type 4: Entirely intramural ← this case (posterior intramyometrial wall, no cavity/serosal extension described)
• Type 5: Subserosal ≥50% intramural
• Type 6: Subserosal <50% intramural
• Type 7: Pedunculated subserosal
• Type 8: Cervical, broad ligament, parasitic

• USG: Anechoic/hypoechoic areas within fibroid, no internal vascularity on Doppler (differentiates from solid component)
• MRI (gold standard): High T2 signal within the fibroid mass (fluid); MRI is superior for mapping exact location, number, depth of intramural extension, and proximity to endometrial cavity — critical for surgical planning
• MRI sensitivity for submucous fibroids: 100%, specificity: 91% (Berek & Novak)
• SIS (saline infusion sonography): Assess endometrial cavity involvement

• AUB is primarily associated with submucosal (Type 0, 1, 2) fibroids because they distort the endometrial cavity and increase surface area/vascularity
• Type 4 purely intramural fibroids have no direct endometrial contact, hence no AUB
• The FIGO data: Hemoglobin <12 most strongly correlated with Type 0 fibroids; intramural fibroids without cavity distortion rarely cause heavy bleeding
• Trap question alert: HOD may ask "then what is causing the abdominal pain and distension?" → See Section 2

1. Uterine leiomyoma (most likely) — benign
2. Leiomyosarcoma (LMS) — must always be excluded; prevalence ~1/1,960 to 1/1,429 surgeries for presumed fibroids (Pritts meta-analysis, 133 studies; AHRQ update)
3. Adenomyoma / focal adenomyosis
4. Ovarian mass (right ovarian cyst, dermoid, endometrioma) — assess separately
5. Broad ligament fibroid
6. Retroperitoneal sarcoma
7. Cervical fibroid

🔷 SECTION 2: SYMPTOM ANALYSIS

• Cystic degeneration causes ischemic pain as fibroid outgrows blood supply
• Large fibroid (12×10 cm) causes pressure symptoms, pelvic heaviness, and dull aching
• Management of pain from degeneration: Analgesics (NSAIDs/paracetamol) + observation — usually self-limiting
• Torsion of pedunculated fibroid can cause acute severe pain (not the case here — this is intramural)
• Red degeneration (typically in pregnancy): fever + localized tenderness + leukocytosis — exclude here

• Posterior fibroid of 12×10 cm compresses the rectosigmoid → intermittent constipation, tenesmus, altered bowel habits
• Must exclude: rectal/sigmoid invasion (rare), extrinsic compression
• Clinical significance: Large posterior fibroid makes abdominal myomectomy technically challenging — posterior uterine incision risks opening uterine cavity; difficult hemostasis; adhesions to bowel postoperatively
• HOD trap: "What about colorectal malignancy?" → Should be considered and ruled out (colonoscopy if needed, especially intermittent stool passage over 1 year)

• Urinary frequency/urgency/retention is typical of anterior/fundal/large fibroids pressing on the bladder
• Posterior fibroid is away from the bladder → bladder habits normal (consistent with clinical findings)
• UAE studies: 35% reduction in uterine volume led to 68% improvement in urinary symptoms (Berek & Novak)

🔷 SECTION 3: FERTILITY CONSIDERATIONS

• Myomectomy is the procedure of choice for symptomatic fibroids in women desiring fertility
• Key fertility concerns:
  1. Large posterior intramural fibroid → may distort endometrial cavity → implantation failure
  2. Post-myomectomy intrauterine adhesions (Asherman's)
  3. Post-myomectomy uterine scar → risk of uterine rupture in future pregnancy
  4. Recurrence of fibroids (20–25% within 10 years)
• Victor Bonney (1931): "Restoration and maintenance of physiologic function is the ultimate goal of surgical treatment" — still the guiding principle
• Counsel patient: surgery → adequate healing time → at least 6–12 months before attempting conception post-myomectomy

• Overall uterine rupture rate post-myomectomy: 0.93% (7/756 viable deliveries; 11 studies, 1,034 pregnancies)
• Trial of labor (TOL) after myomectomy: 0.47% rupture rate — similar to TOL after previous LSCS (0.5–1%)
• Before onset of labor: 1.52% rupture
• 5 of 7 ruptures occurred before 36 weeks
• Posterior intramural myomectomy → deeper uterine wall incision → higher scar risk than subserosal
• After laparoscopic myomectomy: rupture associated with failure to do multilayer closure, use of monopolar/bipolar energy for hemostasis (devascularizes myometrium, impairs healing)
• Recommendation: Elective cesarean section in subsequent pregnancy after myomectomy of large/posterior fibroid — do NOT allow TOL unless adequately counseled

1. Wait minimum 6–12 months before conception (allow scar maturation)
2. Register antenatal care early; serial USG for scar integrity
3. Delivery by elective LSCS (given posterior intramural, large size, multilayer closure)
4. Watch for signs of uterine rupture in pregnancy — pain, fetal distress, bleeding
5. Fibroid recurrence counseling — 20–25% recurrence; may need repeat surgery
6. Ovarian reserve assessment — at 37 years, AMH, AFC to counsel on fertility timeline

🔷 SECTION 4: SURGICAL MANAGEMENT

• Open (Abdominal) Myomectomy is the preferred approach for:
  • Fibroid >10 cm (this is 12×10 cm)
  • Multiple fibroids (assess on MRI)
  • Posterior intramural location
  • Need for multilayer closure (critical for fertility preservation)
• Laparoscopic Myomectomy can be attempted by experienced surgeons:
  • Case series: feasible up to 15 cm (2 conversions in 144 women with mean 7.8 cm; 3 conversions in 332 women up to 15 cm)
  • Requires: intracorporeal suturing expertise, careful hemostasis, proper morcellation
  • Benefit: Less pain, faster recovery, reduced blood loss (meta-analysis: 6 RCTs, 576 patients)
  • Operative times are longer
• Morcellation concern: Risk of occult LMS dissemination → use contained in-bag morcellation or mini-laparotomy extraction — FDA restrictions on power morcellation since 2014
• Robotic myomectomy: no measurable advantage over laparoscopic in expert hands

1. MRI pelvis: Map exact location, number of fibroids, cavity involvement, proximity to endometrial cavity and posterior cul-de-sac, rule out adenomyosis
2. Complete blood count: Rule out anemia
3. Tumor markers: CA-125 (elevated in LMS, endometriosis), LDH (elevated in LMS) — though non-specific
4. GnRH agonist (Leuprolide/Triptorelin): 3–6 months preoperatively
   • Reduces fibroid volume by 30–50%
   • Stops bleeding → corrects anemia (74% patients achieve Hb >12 with GnRH-a + iron)
   • Creates pseudomenopause → softens fibroid, reduces vascularity → less intraoperative blood loss
   • Caution: Makes tissue planes less distinct → may increase risk of incomplete removal
   • Stop 1 month before surgery
5. Iron therapy (IV iron preferred): IV iron increases Hb 3.0 g/dL vs 0.8 g/dL with oral iron (RCT data); consider if anemic
6. Bowel prep: Given posterior fibroid abutting rectum
7. Ureteric stents (urological consult): Consider if mass distorting ureteral anatomy
8. Blood grouping and cross-matching + consent for hysterectomy (in case of uncontrollable hemorrhage)
9. Cell saver/tranexamic acid preparation

1. Incision: Pfannenstiel or midline vertical (for 12 cm fibroid, vertical preferred for access)
2. Vasopressin injection: Dilute vasopressin (20 units in 100 mL saline) into myometrium → vasospasm → reduced blood loss
3. Tourniquet / Vascular clamps: Uterine/ovarian vessel occlusion
4. Incision on fibroid: Transverse/vertical incision on posterior uterine wall over the fibroid
5. Enucleation: Sharp/blunt dissection of the fibroid from the pseudocapsule
6. Posterior location hazards:
   • Proximity to rectosigmoid → risk of bowel injury
   • Proximity to uterine vessels and ureter
   • Risk of entering uterine cavity → increases Asherman's risk
7. Multilayer closure of myometrium: Mandatory — reduces risk of uterine rupture; no dead space
8. Avoid excessive electrosurgery on myometrium (impairs healing → rupture risk)
9. Adhesion prevention agents: Interceed, Seprafilm on posterior surface
10. Specimen: Send for histopathology to rule out LMS

• Hemorrhage → conversion to hysterectomy (consent mandatory)
• Bowel injury (posterior fibroid)
• Ureteric injury
• Inadvertent entry into uterine cavity

• Infection, wound dehiscence
• Intrauterine adhesions (Asherman syndrome) → infertility
• DVT/PE
• Uterine rupture in subsequent pregnancy

• Fibroid recurrence: ~20–25% within 10 years; higher in younger patients and those with multiple fibroids
• Need for repeat surgery
• Failed fertility despite myomectomy

🔷 SECTION 5: MEDICAL AND ALTERNATIVE TREATMENTS

• GnRH agonists (leuprolide, goserelin, triptorelin):
  • Reduce volume 30–50% over 3–6 months
  • Not curative — fibroids regrow after stopping (within 3–6 months)
  • Used as bridge to surgery or to correct anemia
  • Side effects: hypoestrogenic symptoms (hot flashes, bone loss)
  • Add-back therapy (norethisterone/estrogen) prevents bone loss
• Ulipristal acetate (selective progesterone receptor modulator):
  • Effective but regulatory concerns (hepatotoxicity) — withdrawn in many countries
• Mifepristone (antiprogestin): Reduces fibroid size; limited data
• UAE (Uterine Artery Embolization):
  • Reduces fibroid volume ~35–40%
  • NOT recommended when fertility preservation is the primary goal — risk of ovarian damage, uterine ischemia, impaired implantation, placental complications
  • Can be considered if surgery is contraindicated
• Focused Ultrasound (MR-HIFU): Non-invasive; limited data for large fibroids; not for fertility-seeking patients (yet)
• Observation: Acceptable if asymptomatic — 77% of women with mild symptoms do not worsen at 1 year

🔷 SECTION 6: CLASSIC HOD TRAP QUESTIONS

• Answer: Do NOT forcefully separate. Obtain a colorectal surgeon; consider staged procedure. If separation risks bowel injury → leave fibroid remnant, close, complete surgery safely.

• Answer: Raise suspicion for leiomyosarcoma. Cannot differentiate from benign fibroid preoperatively with certainty. Counsel patient about LMS risk (1/1,429 to 1/1,960 surgeries). Proceed to surgery; send specimen urgently for frozen section/histopathology. If LMS confirmed → staging, oncology referral, potentially hysterectomy + BSO.

• Answer: Elevated LDH-3 is associated with LMS. LDH-3 / total LDH ratio >0.7 is suspicious for malignant degeneration (though not highly sensitive/specific). This would prompt more thorough counseling and surgical planning.

• Answer: Given 12×10 cm size with symptoms (pain, bowel compression, progressive distension) + fertility desire — delay carries risks:
  • Further fibroid growth (9% per year average)
  • Worsening bowel/bladder symptoms
  • Increasing surgical difficulty
  • Reduced ovarian reserve with age (AMH declines)
  • Recommend surgery sooner than later, with pre-op GnRH agonist for 3 months to optimize conditions

• Answer: Yes — to rule out submucous component, endometrial polyp, or cavity distortion not apparent on USG. A Type 4 fibroid may have subtle endometrial proximity. Also to document baseline endometrial cavity integrity before myomectomy.

• Answer: Minimum 6–12 months. Most guidelines recommend 12 months for large posterior intramural fibroids with deep myometrial entry and multilayer closure, to allow adequate scar maturation before the mechanical stress of pregnancy.

🔷 SECTION 7: PATHOLOGY QUESTION

• Answer: Mitotically active leiomyoma (benign) — WHO criteria: 10–15 mitoses/10 HPF, no atypia, no coagulative necrosis. Often seen in women taking exogenous hormones or in pregnancy. Not malignant. No additional treatment needed.

• Answer: LMS requires ALL THREE:
  1. ≥10 mitoses/10 HPF
  2. Diffuse moderate-to-marked nuclear atypia
  3. Coagulative (ischemic) tumor cell necrosis
  • LMS: 5-year survival Stage I = 61%; Stages III–IV = ~30%

Summary Checklist for Your HOD Round

1. FIGO Type 4 — this fibroid; know all 8 types by heart
2. Cystic degeneration — outgrown blood supply, no relationship to symptoms
3. No AUB because it's not submucosal — the trap question HODs love
4. LMS prevalence — 1 in 1,429 to 1 in 1,960 (Pritts meta-analysis + AHRQ)
5. Uterine rupture — 0.47% with TOL, 1.52% before labour; multilayer closure is non-negotiable
6. GnRH agonist 3 months preop — volume reduction 30–50%, correct anemia
7. Open myomectomy preferred for 12 cm posterior fibroid — but must know laparoscopic feasibility data (up to 15 cm in expert hands)
8. Consent for hysterectomy — mandatory even in fertility-preserving cases
9. 12 months before conception after deep posterior myomectomy
10. Elective LSCS in next pregnancy

🔷 SECTION 8: MEDICAL MANAGEMENT — DEEP DIVE

• GnRH agonists (leuprolide, goserelin, triptorelin) initially cause a flare effect (transient rise in LH/FSH for 1–2 weeks)
• Followed by downregulation of pituitary GnRH receptors → profound suppression of LH and FSH
• Resulting hypo-estrogenic state → fibroids lose their estrogen-driven growth stimulus → volume reduction
• Also reduce fibroid vascularity (reduces intraoperative blood loss)
• Key numbers to know:
  • Fibroid volume reduced by 30%, total uterine volume by 35% after 6 months
  • Reduction is mostly in the first 3 months
  • After stopping: menses returns in 4–8 weeks, uterine size returns to pretreatment levels in 4–6 months
  • 64% remained asymptomatic 8–12 months after treatment (Berek & Novak)

• Side effects occur in 95% of women
• Only 8% discontinue due to side effects
• Management: Add-back therapy — low-dose estrogen + progestin to reduce hypoestrogenic symptoms and bone loss while continuing GnRH-a for long-term use
• Maximum recommended duration without add-back: 6 months

• GnRH antagonists (relugolix, elagolix, linzagolix): Act by competitive blockade of GnRH receptors — no initial flare effect, immediate suppression of FSH/LH
• Oral daily formulations → convenient for patients
• Elagolix (Orilissa): First oral GnRH antagonist approved; dose-dependent suppression
• Relugolix combination tablet (Myfembree): Relugolix + estradiol + norethindrone — approved specifically for fibroid-associated heavy bleeding; the add-back is co-formulated
• Latest evidence (Meta-analysis, Sánchez Martín et al., Arch Gynecol Obstet 2025 [PMID 39821450]): GnRH antagonists effectively reduce fibroid volume and bleeding; favorable safety profile
• Advantage over agonists: No flare, faster onset, oral route, lower bone loss with add-back co-formulated
• In this patient: Can be used as preoperative preparation — but fertility data is still emerging; not first-line over surgery for large symptomatic fibroid

• NSAIDs: NOT effective for fibroid-associated heavy menstrual bleeding — randomized data (Berek & Novak): 36% decrease in idiopathic HMB but no decrease in fibroid-related HMB
• Tranexamic acid (1.3 g TID for 3–5 days during menses): Pooled RCT analysis shows significant reduction in mean menstrual blood loss vs placebo in women with fibroids — useful for symptomatic HMB
• However, this patient has no AUB — tranexamic acid not indicated currently, but note its role intraoperatively (reduce surgical blood loss)
• Intraoperative tranexamic acid: IV 1g pre-incision + 1g 3h later — reduces blood loss at myomectomy

🔷 SECTION 9: UAE — DETAILED QUESTIONS

1. Interventional radiologist performs percutaneous femoral artery cannulation
2. Catheter advanced to uterine arteries under fluoroscopy
3. Embolization with polyvinyl alcohol (PVA) particles, gelatin sponges, or tris-acryl gelatin microspheres
4. Bilateral occlusion until slow/no flow documented
5. Radiation exposure: ~15 cGy (equivalent to 1–2 CT scans)

• Fibroid/uterine volume decreases significantly, persists up to 5 years (EMMY trial)
• BUT: 28% of women undergo subsequent hysterectomy
• Other reinterventions: hysterectomy 17.5%, repeat myomectomy 8.8%, repeat embolization 6.3%
• UAE has higher rate of minor complications vs surgery (Cochrane review)
• UAE was associated with higher rate of requiring surgical intervention within 2–5 years

1. Fertility desire is the primary goal — UAE has unclear effects on fertility; associated with increased miscarriage risk (Homer & Saridogan, Fertil Steril 2010); interventional radiologists themselves advise against UAE when fertility is desired
2. Risk of ovarian failure from non-target embolization of ovarian vessels
3. Large posterior 12 cm fibroid — less likely to have complete response to UAE alone
4. ACOG recommendation: Women considering UAE must have thorough gynecological evaluation with collaboration between gynecologist and interventional radiologist

• Occurs in majority of patients after UAE
• Features: fever, malaise, nausea, vomiting, pelvic pain — begins 24–48h post-procedure
• Due to ischemic necrosis of fibroid tissue releasing inflammatory mediators
• Usually self-limiting within 1 week; managed with NSAIDs, antiemetics, hydration
• Must distinguish from septic complications (fibroid infection/expulsion)

🔷 SECTION 10: SCENARIO-BASED TRAP QUESTIONS

1. Ileus — most common post-abdominal surgery; bowel sounds absent, no fever usually
2. Wound infection — check wound
3. Intra-abdominal infection / pelvic abscess — especially if fibroid had cystic degeneration (infected cavity)
4. Bowel injury — missed intraoperative bowel entry (posterior fibroid close to rectosigmoid)
5. Hematoma — blood pool at myomectomy site
6. Deep vein thrombosis / PE — fever + tachycardia

• Vitals, clinical exam (abdomen, wound, PV)
• CBC with differential, CRP, blood cultures, urine culture
• Pelvic/abdominal USG or CT scan with contrast
• IV antibiotics (broad spectrum covering gram negatives + anaerobes — cefoperazone-sulbactam or piperacillin-tazobactam + metronidazole)
• If bowel injury confirmed → urgent re-laparotomy

• Uterine rupture at scar site — obstetric emergency
• Posterior intramural myomectomy scar is at highest risk
• Features: sudden severe abdominal pain, loss of fetal heart tones, maternal tachycardia/hypotension, "loss of uterine contour" on palpation
• Management:
  • Immediate IV access, cross-match, call anesthetic + neonatal teams
  • Emergency laparotomy + cesarean
  • Repair uterine defect if possible; hysterectomy if uncontrollable bleeding
• Prevention: counsel all post-myomectomy patients → register early antenatal; elective LSCS at 37–38 weeks; do NOT allow labour to establish if large posterior myomectomy scar

• Immediately recognize and close the endometrium in a separate layer (before closing myometrium)
• Use fine absorbable suture (polyglactin 2-0) to close endometrium without inverting it
• Then close myometrium in multiple layers
• Implications:
  1. Risk of intrauterine adhesions (Asherman syndrome) → secondary infertility
  2. Post-op hysteroscopy at 6 weeks to check cavity
  3. Consider post-op estrogen therapy (conjugated estrogen 2.5 mg/day × 30–60 days) to promote endometrial regeneration and prevent adhesions
  4. In future pregnancy → mandatory elective LSCS (cavity entry = full-thickness scar)
  5. Document in operation notes — critical for future obstetric care

• Cumulative recurrence rate: ~20–25% within 10 years
• Younger patients (like this 37-year-old) have higher recurrence risk — more reproductive years ahead with estrogen exposure
• Multiple fibroids at time of surgery → higher recurrence
• Sonographically detectable new fibroids appear in up to 50–60% at 5 years but most are small and asymptomatic
• Symptomatic recurrence requiring repeat surgery: ~10–15%
• If she has a completed family after this surgery, and recurrence is symptomatic → hysterectomy is definitive
• GnRH agonist post-myomectomy does NOT prevent recurrence

• AMH 0.8 ng/mL = diminished ovarian reserve (normal for age >35 is ≥1.0 ng/mL; significantly reduced <1.0 ng/mL)
• Implications:
  1. Limited time window for fertility — must not delay surgery unnecessarily
  2. After myomectomy, minimum 6–12 months recovery → she will be ~38–39 years at conception attempt
  3. At 37 years with AMH 0.8 → consider early referral to ART/IVF specialist simultaneously with surgical planning
  4. Ovarian reserve can be further reduced by: inadvertent ovarian vessel injury at myomectomy, UAE (contraindicated), excessive electrosurgery near cornua
  5. Counsel honestly: natural conception may be difficult; IVF may be needed; egg freezing (oocyte cryopreservation) should be discussed NOW before surgery further impacts ovarian reserve

• MR-HIFU (Exablate): Non-invasive ultrasound-based thermal ablation guided by MRI
• Mechanism: Focused ultrasound energy → thermal coagulation necrosis within fibroid
• Approved by FDA (2004) for symptomatic fibroids
• Limitations for this case:
  1. Best for anterior, accessible fibroids — posterior fibroid (this case) may be shadowed by uterus/bowel; poor access
  2. Not recommended if fertility preservation is primary goal — limited safety data in pregnancy outcomes
  3. Fibroid size >10 cm → multiple treatment sessions needed; incomplete response likely
  4. No tissue diagnosis possible (LMS cannot be excluded)
  5. Post-procedure: some patients need repeat treatment or surgery

🔷 SECTION 11: ANATOMY & PHYSIOLOGY QUESTIONS

1. Proximity to rectosigmoid → adhesions, risk of bowel injury
2. Proximity to uterosacral ligaments and ureter at the posterior broad ligament — ureteric injury risk
3. Limited visualization — posterior wall is less accessible in deep pelvis
4. Adhesions from pelvic inflammatory disease or endometriosis more common posteriorly (pouch of Douglas)
5. Posterior myometrial closure is technically harder to achieve adequate hemostasis
6. Post-myomectomy adhesions more likely posteriorly → bowel adhesion, dyspareunia, secondary infertility (tubes may get involved)
7. After closure, blood can pool in the pouch of Douglas — drain placement may be needed

• Uterine artery = branch of the anterior division of internal iliac (hypogastric) artery
• Crosses the ureter (anteriorly) at the level of the internal cervical os — "water under the bridge" — at risk during ligation
• Enters the uterus at the level of the isthmus laterally
• Gives ascending branch (supplies body and fundus) and descending branch (cervical and vaginal branches)
• During myomectomy: vasopressin injected into myometrium causes vasospasm of terminal uterine artery branches → reduces blood loss
• Alternatives for hemorrhage control: bilateral uterine artery ligation (O'Leary stitch), internal iliac ligation, or interventional radiology

• Junctional zone (JZ): Inner myometrium seen on MRI T2 — low signal intensity band between endometrium and outer myometrium
• Normal JZ thickness: <8 mm
• JZ >12 mm (or >15 mm) → suggests adenomyosis (diffuse) on MRI
• Relevance here:
  1. Adenomyosis can co-exist with fibroids (complicates surgery; no surgical cure — no clean plane like fibroid pseudocapsule)
  2. Focal adenomyoma can be confused with intramural fibroid on USG
  3. MRI pre-op must specifically assess JZ to exclude adenomyosis — if present, affects prognosis for fertility and need for additional medical treatment (dienogest, GnRH-a post-op)

🔷 SECTION 12: ETHICS, CONSENT & COUNSELLING

• Respect patient autonomy — document clearly
• Strategies to minimize blood loss:
  1. Pre-op GnRH agonist 3 months (reduce vascularity)
  2. Pre-op IV iron to maximize Hb (target Hb >12 pre-surgery)
  3. Epoetin alfa (recombinant EPO) pre-op — increases Hb by 1.6 g/dL, reduces transfusion rates (RCT data; Berek & Novak)
  4. Intraoperative: vasopressin, tourniquet technique, cell saver (autologous blood salvage)
  5. Tranexamic acid IV intraoperatively
  6. Meticulous surgical technique, bilateral uterine artery clamps
• Threshold decision: If intraoperative hemorrhage is life-threatening → document that life-saving transfusion was discussed; if patient is conscious, reconfirm refusal; if patient is unconscious/incapacitated → legal/ethical considerations depend on jurisdiction
• Involve ethics committee + legal team pre-operatively in such cases

• The patient is the primary decision-maker, not the husband — medicolegal principle (patient autonomy)
• Patient has clearly expressed desire for fertility preservation
• Husband's preference is noted but cannot override patient's consent
• Counsel both together:
  1. Myomectomy is a safe alternative to hysterectomy — comparable complication rates (Berek & Novak: less intraoperative injury risk vs hysterectomy)
  2. Explain fibroid recurrence and possibility of future hysterectomy
  3. Document informed consent signed by patient
• Do not dismiss the husband — involve him respectfully in shared decision-making, but clarify the legal and ethical framework

🔷 QUICK-FIRE DEFINITIONS YOUR HOD MAY ASK

🔷 SECTION 13: HOD'S FINAL CLINCHER QUESTIONS

1. Pressure with warm packs — 5 minutes
2. Ensure vasopressin still effective (if used)
3. Additional figure-of-8 sutures into the bleeding bed
4. Topical hemostatic agents: Surgicel (oxidized cellulose), Gelfoam, Floseal (thrombin + gelatin matrix)
5. Bilateral uterine artery ligation (O'Leary stitch) at uterine isthmus
6. Internal iliac artery ligation (if above fails)
7. B-Lynch suture equivalent for diffuse ooze from uterine surface (compression suture)
8. Packing + planned relook at 24–48h
9. If all fails + hemodynamically unstable → hysterectomy (consent already obtained)
10. Call vascular/interventional radiology for intraoperative uterine artery embolization if available

1. Indication (symptomatic large posterior fibroid, fertility preservation)
2. Consent obtained including hysterectomy possibility
3. Blood transfusion consent
4. GnRH agonist preoperative course
5. Incision type and rationale
6. Fibroid size, site, weight, number
7. Whether uterine cavity was entered (YES/NO — critical)
8. Layers of closure (multilayer — documented explicitly)
9. Estimated blood loss + transfusion given
10. Hemostatic agents used
11. Adhesion barrier applied
12. Drain placed (yes/no, site)
13. Specimen sent for HPE